AVH – ReGenerCell Skin Regeneration Technology Decreases Size and Pain in Chronic Wounds
Chronic Wounds Data Presented at Skin Regeneration Symposium in Cambridge, UK. Cambridge, United Kingdom, 20 April 2016. Link here.
AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
/in Armata PharmaceuticalsSAN DIEGO, April 20, 2016– Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing first-in-man Phase I clinical trial for chronic rhinosinusitis patients treated with AmpliPhi’s proprietary phage cocktail AB-SA01. The first cohort, […]
Skin Regeneration Technology Critical to Recovery and Quality of Life in Burns Patients Say Top Clinicians
/in Portfolio CompaniesExtensive burns research data presented at Skin Regeneration Symposium in Cambridge, UK. – ReCell technology improves burn wound healing, reduces scarring, discoloration and itching – ReCell effective for extreme burns in emergency situations – 95% healing in less than 2 months achieved with ReCell for explosion patient with 70% burn – Leading EU hospital incorporating […]
AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon
/in Armata Pharmaceuticals, Portfolio CompaniesSAN DIEGO, April 14, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon. Under the terms of the agreement, AmpliPhi has the […]
AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
/in Portfolio CompaniesSAN DIEGO, April 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix […]
ADR Appoints Senior Executive and Establishes Operations in Europe
/in Portfolio CompaniesMelbourne, Australia, 31 March 2016. Adherium Limited (ASX:ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, has appointed a new Senior Vice President of Business Development and has established an operating entity in the UK to serve the European market. Announcement link here.
Adherium Establishes North American Operations and Appoints Senior Vice President of Business Development to Lead Market Expansion
/in Portfolio CompaniesMelbourne, Australia, March 23, 2016. Link to announcement here.
RXB – Trading Update
/in Portfolio Companies, Rex Bionics16 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to provide an update on trading since the Company’s Interim Results Statement, released on 8 December 2015. The Directors re-iterate their sales guidance, provided in the Interim Statement, that […]
RXB – Agreement with the United States Army
/in Portfolio Companies, Rex Bionics– Modification of REX to accommodate patients with lower limb loss – Co-operation with Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, US – Potential for “Broad Applicability across the Department of Defense and the Veterans Administration” 11 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology […]
Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis
/in Pharmamark, Portfolio CompaniesEffectiveness Submission to the FDA-CVM on Track for 2Q 2016. DUBLIN, Ireland, March 08, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of […]